Renewed attention to prostate cancer this week has come with a familiar problem attached. Men asking whether they should be screened are finding that expert bodies do not fully agree, and that the disagreement is real rather than a communication failure.
Hunter Biden told the BBC's Newsnight that his father's cancer has spread further, describing the former president's condition as "very painful" and very debilitating. Joe Biden, 83, was diagnosed in May 2025 with an aggressive form of prostate cancer that had already metastasized to bone, and his office said at the time it appeared hormone-sensitive.
Nothing in that account establishes what screening would or would not have changed in his case, and no one outside his medical team is in a position to say. What it has done is send a large number of men to search engines with a question that has no single correct answer.
Where the Guidance Currently Stands
The U.S. Preventive Services Task Force recommends that men aged 55 to 69 have the option to undergo periodic prostate-specific antigen screening, framed explicitly as an individual decision.
The task force states that before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms with a clinician and to incorporate their own values and preferences into the decision.
It describes the benefit as a small potential reduction in the chance of dying from prostate cancer and names the harms directly: false-positive results, overdiagnosis and overtreatment, and treatment complications.
That framing reflects a specific biological reality. Many prostate cancers grow so slowly that a man will die with the disease rather than from it. Detecting those cancers can lead to biopsies, surgery, or radiation that carry real risks of incontinence and erectile dysfunction, for a cancer that would never have caused symptoms.
The counterweight is equally real. Prostate cancer will be diagnosed in about 333,830 men in the United States this year and will kill about 36,320, according to the American Cancer Society. One in eight men will be diagnosed in their lifetime.
The Case for More Aggressive Screening
Those who argue that current guidance is too cautious make several points that deserve to be stated in full rather than summarized dismissively.
Screening detects prostate cancer before symptoms appear in most men who are screened routinely. By the time symptoms of advanced disease emerge, treatment intent generally shifts from cure to control.
The overtreatment problem, this argument holds, has been substantially addressed since the studies underpinning cautious guidance were conducted. Active surveillance, in which low-risk cancers are monitored rather than treated immediately, is now standard practice. MRI-guided biopsy reduces unnecessary biopsies and improves detection of clinically significant disease. Risk stratification tools help separate cancers that need treatment from those that do not. Under this view, discouraging the test to avoid overtreatment addresses a problem that better management already mitigates.
Advocates also note that a PSA test is an ordinary blood draw rather than an invasive procedure, and that the harms attributed to screening flow from what happens after an abnormal result, not from the test itself.
Guidance from professional urology bodies has generally been more permissive than that of the task force, setting out shared decision-making frameworks that begin earlier for many men and continue later in life, based on health status rather than a fixed age cutoff.
Where Nearly Everyone Agrees on Higher Risk
The area of genuine consensus is that some men should start the conversation earlier, and this is the part most likely to be actionable for a reader.
Black men face substantially higher prostate cancer incidence and mortality than white men in the United States. Men with a father or brother diagnosed with prostate cancer carry an elevated risk, and risk rises further with multiple affected relatives or a relative diagnosed young. Known BRCA1 or BRCA2 mutations and a family history of certain other cancers also raise risk.
For these groups, major guidance converges on beginning the screening discussion in the forties rather than at 55, and clinicians and advocacy organizations broadly support that.
Age is the dominant risk factor overall. Six in ten prostate cancer cases are diagnosed in men 65 and older, with an average age at diagnosis of 67. Men under 40 are rarely affected. It is the second most common cancer in men in the United States.
The task force does not recommend routine PSA screening for men 70 and older, on the reasoning that the benefit shrinks and the harms grow as competing causes of death become more likely. Clinicians vary in how strictly they apply that boundary to healthy older men with long life expectancy.
Preparing for the Conversation
The decision belongs to a man and his clinician, and the useful preparation is specific rather than general.
Know your family history before the appointment. Which relatives, what cancer, at what age. That information changes the recommendation more than almost anything else you can bring.
Reasonable questions include: given my age, race, and family history, what is my estimated risk? If my PSA comes back elevated, what happens next, and would an MRI come before a biopsy? If a cancer is found, would active surveillance be an option for me? What are the specific rates of incontinence and erectile dysfunction with the treatments this practice performs?
Symptoms are not a screening strategy because early prostate cancer typically produces none. Problems urinating, a weak or slow stream, increased urinary frequency, or blood in urine or semen warrant evaluation, though these are more often caused by benign prostate enlargement than by cancer. New persistent bone pain, particularly in the back, hips or pelvis, alongside unexplained weight loss, warrants prompt evaluation.
Men without insurance can access screening discussions through federally qualified health centers on a sliding fee scale, and some hospital systems and advocacy organizations run free screening events, though a screening event without a plan for follow-up is of limited value.
Guidance from the task force and professional bodies is periodically reviewed and updated. MedicalDaily will report any revision.
Key Questions Answered
What does current federal guidance say? Men aged 55 to 69 should have the option to undergo periodic PSA screening after discussing benefits and harms with a clinician.
Why isn't screening simply recommended for everyone? Many prostate cancers grow slowly enough never to cause symptoms, and detecting them can lead to treatment carrying risks of incontinence and erectile dysfunction.
What do those who favor more screening argue? That active surveillance, MRI-guided biopsy, and risk stratification have reduced the overtreatment problem that the cautious guidance was built around.
Who should start the discussion earlier? Black men, men with a father or brother diagnosed with prostate cancer, and men with known BRCA1 or BRCA2 mutations, generally in their forties.
What about men over 70? The task force does not recommend routine screening for those aged 70 and older, though clinicians vary in applying that to healthy men with long life expectancy.
Are there early symptoms to watch for? Early disease usually causes none. Urinary changes warrant evaluation but are more often caused by benign enlargement.
How common is prostate cancer? About 333,830 diagnoses and 36,320 deaths are expected in the United States this year, with one in eight men diagnosed in their lifetime.
